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Abstract Lymphovascular invasion (LVI) and histologic
grade are clinical parameters of high prognostic value in breast
cancer and indicate the level of tumor aggressiveness. Many
studies have focused on the association of breast cancer sub-
types with gene expression and chromosomal profiles, but
considerably less genomic information is available regarding
traditional prognostic factors such as histologic grade and
LVI. We studied by array-CGH a group of 57 invasive ductal
carcinomas of the breast to outline the DNA copy number
aberration (CNA) profile linked to high histologic grades and
LVI. Selected CNAs were validated using real-time quantita-
tive PCR (qPCR). Furthermore, gene expression analysis was
performed in a subset of 32 of these tumors, and findings were
integrated with array-CGH data. Our findings indicated an
accumulation of genomic alterations in high-grade breast tu-
mors compared to low-grade samples. Grade III tumors
showed higher number of CNAs and larger aberrations than
low-grade tumors and displayed a wide range of chromosomal
aberrations, which were mainly 5p, 8q, 10p, 17q12, and 19
gains, and 3p, 4, 5q proximal, 9p, 11p, 18q, and 21 losses. The
presence of LVI, a well-established prognostic marker, was
not significantly associated with increased genomic instability
in comparison to breast tumors negative for LVI, considering
the total number of chromosomal alterations. However, a
slightly increase in the frequency of specific alterations could
be detected in LVI-positive group, such as gains at 5p, 16p,
17q12, and 19, and losses at 8p, 11q, 18q, and 21. Three
newly reported small-scale rearrangements were detected in
high-risk tumors (LVI-positive grade III) harboring putative
breast cancer genes (amplicons at 4q13.3 and 11p11.2, and a
deletion at 12p12.3). Furthermore, gene expression analysis
uncovered networks highlighting S100A8,MMP1, andMED1
as promising candidate genes involved in high-grade and LVI-
positive tumors. In summary, a group of genomic regions
could be associated with high-risk tumors, and expression
analysis pinpointed candidate genes deserving further inves-
tigation. The data has shed some light on the molecular
players involved in two highly relevant prognostic factors
and may further add to the understanding of the mechanisms
of breast cancer aggressiveness.
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Introduction
Breast cancer is a significant cause of cancer-related death
worldwide [1]. Despite significant advances in diagnosis and
treatment, several considerable clinical and scientific prob-
lems remain unresolved. Invasive ductal carcinomas (IDC)
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of no special type (NST) represent 80% of all invasive tumors
of the breast. IDC can be associated with a poorer prognosis
than certain special types of breast cancer (such as tubular and
mucinous carcinomas) and shows significant biological het-
erogeneity. Traditional variables, such as tumor size, axillary
nodal status, histologic grade, and lymphovascular invasion
(LVI) status, are part of risk assessment and deliver significant
prognostic information, albeit with limited predictive value
[2–6].
The histologic grade [Scarff-Bloom-Richardson (SBR)]
modified by Elston and Ellis (modified SBR or Nottingham
system) is a widely validated prognostic factor recommended
by the Union for International Cancer Control (UICC, 2009).
This index grades phenotypic aggressiveness according to
morphological criteria based on tubular formation, nuclear
pleomorphism, and mitotic counting [7]. Although many
studies have focused on the association of breast cancer sub-
types with gene expression and chromosomal profiles, con-
siderably less genomic information is available regarding
traditional prognostic factors such as histologic grade and
LVI [8–12].
Recent studies point to the significance of DNA copy
number aberrations (CNAs) in the etiology of cancer with
the number and complexity of these aberrations being indic-
ative of overall prognosis [10, 13–15]. CNA investigation
may assist the identification of regions containing oncogenes
and tumor suppressor genes [16]. Grade III breast tumors
frequently harbor gains at 3q and 5p, and 8q amplifications
[10, 11]. More recently, a 19q12 amplification was detected,
primarily associated with grade III breast tumors in estrogen-
negative samples, which encompasses the CCNE1 gene,
among others [17]. Grade I tumors show less complex karyo-
types with recurrent gain of 16p, as found in estrogen-positive
tumors [11, 18]. However, to the best of our knowledge, no
study has investigated the genomic profile of CNAs related to
the presence of LVI in breast carcinomas.
We performed a study outlining the CNA and gene expres-
sion patterns of invasive carcinomas of the breast to identify
genomic alterations and differentially expressed genes linked
to high histologic grades and LVI.We suggest several genes as
potential biomarkers of breast cancer aggressiveness with the
ultimate goal of improving patient care.
Materials and methods
Study approval and patient samples
This retrospective study was approved by the local Ethics and
Research Committee of A.C. Camargo Cancer Center, São
Paulo, Brazil (#1448/10), and informed consents were obtain-
ed from all patients. Frozen samples from 57 invasive ductal
carcinomas of the breast were retrieved from the A.C.
Camargo Cancer Center Biobank for DNA and RNA extrac-
tions. All selected carcinomas were tested for estrogen recep-
tor, progesterone receptor, and HER2 status, and analyses
followed the ASCO/CAP guidelines [19, 20]. Detailed clinical
characteristics of the 57 breast carcinomas are given in Sup-
plementary Table S1. These tumors were selected because of
their availability as frozen samples.
DNA and RNA isolation
Genomic DNA was extracted according to the procedure of
the Biobank of the institution [21]. Sample quality and quan-
tity were assessed using NanoDrop (Thermo Scientific, Wal-
tham, MA, USA), and molecular weight was checked by
electrophoresis in agarose gels. RNAwas obtained from epi-
thelial cells from invasive ductal carcinomas samples captured
by laser microdissection using the PixCell II LCM system
(Arcturus Engineering, Mountain View, CA, USA). Only
RNA samples with optical density of approximately 2.0 and
RNA integrity number >5.0 were used for microarray exper-
iments [22].
Comparative genome hybridization based on microarrays
We performed comparative genomic hybridization based on
microarrays (array-CGH) in a commercial whole-genome
60K platform containing 60,000 oligonucleotide probes
(Agilent Technologies, Santa Clara, CA, USA; design
21924). A commercially available pool of healthy human
female DNA (Promega, Madison, WI, USA) was used as
the reference DNA. The experimental procedure was per-
formed as recommended by the manufacturer. Scanned im-
ages were processed using Feature Extraction Software ver-
sion 10.7.3.1 (Agilent Technologies). Poor-quality hybridiza-
tions (quality control >0.2) were disregarded [23]. CNAs were
identified with Nexus software 7.0 (BioDiscovery, Haw-
thorne, CA, USA) using the FASST2 segmentation algorithm,
which is an approach based on the Hidden-Markov model that
uses the log2 ratio values of the probes for CNA calling. We
applied the following settings: a minimum of five consecutive
affected probes (effective resolution of ∼200 kb for CNA
calling), a significance threshold set at 10−8, and threshold
log2 ratio Cy3/Cy5 of 0.3 and 1.4 for gain or high copy gain
(named amplicons), respectively, and −0.3 and −1.1 for loss
and homozygous loss, respectively. Copy number variants
reported in the Database of Genomic Variants (DGV, http://
projects.tcag.ca/variation/), CNAs smaller than 50 kb, and
data from the sex chromosomes were excluded. Gene
annotation was performed according to the GRCh37 using
the University of California Santa Cruz Genome Browser
(http://genome.ucsc.edu/cgi-bin/hgGateway). The smallest
common regions of recurrent aberrations were obtained by
implementing the global frequency statistical approach of the
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Significance Testing for Aberrant Copy Number (STAC)
method [24]. The parameters had a minimum differential
threshold of 25 % and had p values of p≤0.05 for LVI and
p≤0.01 for histologic grades. The CNA data of each breast
tumor group were evaluated for number, length, and types of
CNAs (gains, losses, high copy gains, and homozygous
losses), and statistical analyses were performed using
GraphPad Prism v5.0 (Mann-Whitney test to compare two
unpaired groups and Kruskal-Wallis test to compare three
unpaired groups).
Copy number validation by real-time quantitative PCR
Real-time quantitative PCR (real-time qPCR) was performed
on three genes (ADAMTS3 F:CGTAGAAAGCCTTTGGG, R-
:GGTGCATGATGGAACG; HSD17B12 F:CCCTTTAAGCCA
TTCCG, R:GCCAATATTCAAACCGAGC, and RERGL F-
:CCCCACAAAGTTCCTTC, R:CTCATCTGCTCTGAAACT
GG) using the SYBR Green system (Applied Biosystems,
Foster City, CA, USA) on a 7500 System apparatus (Applied
Biosystems, Foster City, CA, USA) with reference DNA
(Promega) for copy number calibration. Values were normal-
ized based on data from the GAPDH (12p13) and P2RX7
(12q24) genes, which were not affected by copy number
changes in these groups of tumors. Duplicates were analyzed
using the comparative 2-ΔΔCt cycle threshold method [25].
Values in the range of 0.8–1.2 indicate two copies, <0.6
indicates copy number loss, and >1.4 was considered a gain.
Microarray gene expression analysis
A subgroup of 32 breast carcinomas was evaluated for gene
expression based on cDNA microarrays using a 244K custom
platform (Agilent Technologies, Santa Clara, CA, USA).
Samples were hybridized following the manufacturer’s proto-
col. Scanned images were processed using Feature Extraction
Software version 10.7.3.1. The identification of genes differ-
entially expressed was performed using the Agilent
GeneSpring GX 12.1 software after subtracting background
and filtering features flagged as not positive, not significant, or
not uniform in normalization (normalization to the 65th per-
centile shift per array, median across all samples per tran-
script). To identify differentially expressed genes, we used
the t test (unpaired with 5 % false-discovery ratio correction)
considering a fold change of |2| with p≤0.05. The genes
belonging to the PAM50 list [26] were excluded from this
analysis since their expression profiles predict intrinsic mo-
lecular subtypes of breast cancer and, consequently, could
interfere with gene changes differentiating tumors according
to histologic grades or lymphovascular invasion status. Inge-
nuity Pathway Analysis (IPA) software was used for the in
silico analysis of the sets of differentially expressed genes.
Interaction networks were obtained using a core analysis tool,
which considered the Ingenuity Knowledge Base (genes +
endogenous chemicals), human species, breast cancer cell
lines, and all types of tissues and primary cells. The selected
networks generated by the program contained at least 40 % of
the set of differentially expressed genes identified in the study.
Results
Table 1 summarizes the frequencies of the clinical categories
in the group of 57 carcinomas of the breast. Of these cases,
21 % were classified as triple-negative (estrogen receptor
(ER)-, progesterone receptor (PR)-, and human epidermal
growth factor receptor 2 (HER2)-negative tumors) [27]. A
total of 2,857 CNAs were identified in all of the breast tumors
profiled (mean of ∼50CNAs per sample). The summary of the
CNA results and the full array-CGH data can be found in
Supplementary Tables S2 and S3, respectively. A complex
pattern of multiple chromosomal gains and losses was identi-
fied in all samples, the most frequent being gains of chromo-
somes 1q, 8q, 16p, and 17q and losses affecting 8p, 9p, 11q,
13q, 16q, and 18q (Fig. 1a).
We performed a statistical comparison between subgroups
of breast tumor samples according to the presence of lymph
Table 1 Clinical characteristics of the group of 57 primary invasive
ductal carcinomas of non-special type of the breast
Clinical variable Category Number (%)
LVIa Positive 25 (43.9)
Negative 32 (56.1)
SBRb I 9 (15.8)
II 17 (29.8)
III 31 (54.4)
Clinical stage I 9 (15.8)
II 21 (36.9)
III 26 (45.6)
IV 1 (1.7)
Axillary lymph node N0 20 (35.1)
N1 19 (33.3)
N2 10 (17.5)
N3 8 (14.0)
Estrogen receptor Positive 33 (57.9)
Negative 24 (42.1)
ERBB2 Positive 5 (8.8)
Negative 52 (91.2)
Triple-negative Yes 12 (21.0)
No 45 (79.0)
a Lymphovascular invasion
b SBR grade, Scarff-Bloom Richardson graduation system (histological
grade)
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node metastasis: tumors from patients without lymph node
metastasis (N0=20 samples) and tumors from patients harbor-
ing lymph node metastasis at diagnosis. Significant differ-
ences were not detected.
Total CNAs and their distribution and type according
to histological grade
We compared different tumor subgroups according to histo-
logic grades to assess the total number of CNAs and the CNA
distribution with regard to the different types of events (gain,
high copy gain, loss, homozygous loss). These results are
detailed in Table 2.
Grade III tumors showed a statistically higher total number of
CNAs compared to grade I (p=0.045) and grade II (p=0.006)
tumors (Mann-Whitney test, Fig. 2a). Additionally, grade III
group had a higher number of gains (p=0.007, Fig. 2b) and
losses (p=0.0148, Fig. 2c) compared to low-grade tumors
(Mann-Whitney test), and the CNAs were larger than those
detected in the grade II group (p=0.0498, Mann-Whitney test;
Fig. 2d).
In a visual inspection, grade III tumors exhibited a wider
range of chromosomal aberrations than grades I and II. In
particular, CNAs detected preferentially or almost exclusively
in this group included the following: gains affecting 5p, 8q, 10p,
17q12 (ERBB2), and 19 and losses at 3p, 4, 5q proximal, 8p, 9p,
11p, 18q, and 21 (Fig. 1b).
Using the STAC statistical analysis, we detected the
smallest common regions of aberrations associated with his-
tologic grade III. Peaks of genomic regions preferentially
present in grade III tumors (minimum threshold of 25%) were
detected in several chromosomes, including peak gains at
5p15, 7p22, 8q22, 8q24, 10p12.1, 19q12, and 20p13 and peak
losses at 4p13p12, 4q34q35, 9p21, 5q11q23, 12p12, and
21q21 (Supplementary Table S4).
In our samples, the manual curation of CNA data from each
tumor sample revealed that the most frequent alteration iden-
tified both in grades I (33.3 %) and II (52.9 %) was a 16p gain,
Fig. 1 Array-CGH genomic profile exhibiting the frequency of DNA
copy number aberrations (CNAs) in the group of invasive ductal carci-
nomas of the breast. The x-axis represents the genomic positions of
chromosomes 1p to 22q, and the y-axis denotes the percentage of gains
(plotted in blue above the 0 % baseline) and losses (plotted in red below
the 0 % baseline) in all selected samples at the specified genomic location
(images adapted from the Nexus Copy Number 7.0 software,
BioDiscovery). chr indicates the chromosome, and n is the number of
samples in each group. a The genomic profile of CNAs (gains and losses)
of all 57 invasive ductal carcinomas of the breast. bCNA profile of breast
tumors grouped according to histologic grade (I, II, and III). c CNA
profile of breast tumors grouped according to lymphovascular invasion
status.
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which was detected only in 15.2 % of the grade III samples
(Fig. 1b, Supplementary Table S4). All breast tumors harbor-
ing the 16p gain were found to be positive for estrogen
receptor.
Total CNAs and their distribution and type according to LVI
status
We also compared the CNA profile of breast tumors according
to LVI status and the results are summarized in Table 2. We
did not detect statistically significant differences between LVI-
positive and LVI-negative groups (p value >0.5 in all
comparisons) regarding the total number of CNAs, the CNA
distribution (number of gain, high copy gain, loss, homozy-
gous loss), and genomic sizes.
Although we did not detect evidence of an increased ge-
nomic instability in LVI-positive breast tumors, some specific
rearrangements could be detected at a slightly higher frequen-
cy in this group compared to the LVI-negative group, such as
gains at 5p, 17q12 (ERBB2), and 19, and losses affecting 8p,
11q, 18q, and 21 (Fig. 1c).
Using the STAC analysis, we detected more frequently
associated with LVI (minimum of 25 % of the samples) two
deletions peaks at 11q24.1 and 11q24.3, encompassing the
Table 2 Total number of DNA copy number aberrations (CNAs), their distribution in each different CNA class (gain, loss, high copy gain, homozygous
loss), and genomic lengths according to histologic grades (SBR) and lymphovascular invasion status (LVI)
Group Total events
(median)
Gains
(median)
Losses
(median)
High copy gains
(mean)
Homozygous losses
(mean)
Mean size (Mb)
(median)
Breast carcinomas (n=57) 2,857 (38.0) 1,477 (23.0) 1,245 (16.0) 122 (2.1) 13 (0.2) 70.2 (27.3)
SBR I (n=9) 290 (21.0) 128 (12.0) 155 (9.0) 7 (0.8) 0 (0) 10.0 (27.0)
SBR II (n=17) 606 (20.0) 315 (10.0) 241 (9.0) 44 (2.6) 6 (0.3) 16.2 (26.6)
SBR III (n=31) 1,961* (60.0) 1,034* (33.0) 849* (25.0) 71 (2.3) 7 (0.2) 48.9* (27.3)
LVI positive (n=25) 1,289 (38.0) 676 (25.0) 558 (14.0) 51 (2.0) 4 (0.2) 33.1 (26.6)
LVI negative (n=32) 1,568 (41.5) 801 (22.5) 687 (17.5) 71 (2.2) 9 (0.3) 40.0 (27.6)
*p<0.05 (statistically significant at this level in the comparison between different SBR grades, Mann-Whitney test)
Fig. 2 Statistical analysis
comparing the DNA copy number
aberration (CNA) events between
different breast carcinoma groups
according to histologic grades.
Asterisks indicate statistical sig-
nificance. a Bar graph of the total
number of CNAs showing signif-
icant differences between tumor
grades I and II compared to grade
III. b Bar graph of the number of
gain events showing significant
differences between tumor grades
I and II compared to grade III. c
Bar graph of the number of loss
events showing significant differ-
ences between tumor grades II
compared to grade III. d Bar
graph of the genomic alteration
sizes of breast tumors showing
significant differences between
grade II tumors compared to
grade III
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OR6M1 and ARHGAP32 genes, respectively, whereas the 16p
gain and a 16q23 loss were detected at a higher frequency in
tumors without LVI (Supplementary Table S5). In fact, the
manual curation of CNA data from each tumor sample re-
vealed that the 16p gain could be detected in about 40% of the
LVI-negative group compared to 24 % of cases presenting
LVI. Considering that all these breast tumor samples carrying
16p gains were found to be positive for estrogen receptor, we
performed a statistical correction (logic regression) which
showed that the 16p gain is a marker independently associated
with LVI-negative status.
Small-scale rearrangements: genomic amplifications
and homozygous losses
We investigated the frequency of six known breast cancer
amplicons [28] excluding 17q12 (ERBB2), and all of them
were frequently detected in grade III tumors as genomic gains
(Table 3). The 19q12 gain was detected exclusively in grade
III tumors (one amplification and nine copy number gains), all
of them negative for estrogen receptor. The smallest common
region affected by this 19q12 gain was restricted to a ∼537 kb
segment at chr19:29,777,917-30,315,215 (GRCh37) in which
only six genes are mapped, including CCNE1. Regarding the
LVI status, the majority of the tumors carrying the 20q13.2
gain (62.5 %) were positive for LVI.
In addition to the abovementioned known breast cancer
amplicons, we detected three small-scale rearrangements
(< 4 Mb) not previously reported, each of them in a different
high-risk tumor (grade III positive for LVI): two amplifica-
tions, one at 4q13.3 (chr4:72,209,104-73,455,050) and the
other at 11p11.2 (chr11:43,830,876-46,190,463); and one ho-
mozygous deletion at 12p12.3 (chr12:17,950,780-
20,811,443). Genes mapped within the two amplified regions
were selected for further copy number validation (Supplemen-
tary Figure S1). Figure 3 displays the homozygous 12p12.3
deletion encompassing the RERGL and PIK3C2G genes,
among others.
The 11p11.2 genomic amplification encompasses, among
others, the HSD17B12 gene. In our cohort, we detected
HSD17B12 gains in association with gains of the COX2 gene,
in a possible 1q31/11p11 co-amplification pattern, here ob-
served in ER-negative high-grade breast tumors.
Copy number status of previously reported breast cancer
driver genes
We scrutinized the copy number status of 33 driver cancer
genes reported as recurrently affected by copy number chang-
es in breast cancer [11, 17, 29–32], which includes the major
genes of the aforementioned amplicons.We also examined the
copy number status of three genes highlighted in the present
study (ADAMTS3, HSD17B12, and RERGL). Different CNA
frequencies affecting these genes were observed according to
histologic grade and LVI status (Fig. 4). A panel of 16 genes
exhibited copy number changes at higher frequencies in high-
grade tumors compared to low-grade samples (losses affecting
PPP2R2A, CDKN2A, MTAP, RERGL, RB1, PTEN, INPP4B
and gains of CCNE1, ERBB2, EGFR, FGFR1, GATA3,MYC,
HSD17B12, ZNF703, and ZNF217; Fig. 4a); conversely, copy
number losses of TP53, CDH1, and NCOR1 were detected
preferentially in low-grade breast tumors. Furthermore,
ERBB2 gains and RERGL losses were more frequent in the
presence of LVI (Fig. 4b).
Gene expression profiling
Table 4 displays the top differentially expressed genes of
the breast tumor groups with their respective fold-change
values (full differential expression analysis can be found in
Supplementary Tables S6 and S7). Histological grade III
tumors exhibited 12 up- and 13 downregulated genes
compared to low-grade tumors (p value <0.001 and fold
change of |5|). We investigated the copy number status of
the detected deregulated genes. The following five genes
displayed a CNA pattern concordant with the expression
level in >15 % of the grade III tumors: S100A8 and
Table 3 Frequency of gains affecting well-known breast cancer amplicons in high-risk breast carcinomas (histologic grade III and lymphovascular
invasion positive)
Known
amplicon
Major gene Total frequency (n
affected)
Frequency among histologic grade III
samples
Frequency among lymphovascular invasion positive
samples
8q24 MYC 38.6 % (22) 81.8 % 45.4 %
8p12 ZNF703/
FGR1
31.6 % (18) 72.2 % 44.4
8p12 FGFR1 29.8 % (17) 64.7 % 47.1 %
19q12 CCNE1 17.5 % (10) 100 % 55.5 %
20q13.2 ZNF217 14.0 % (8) 62.5 % 62.5 %
11q13 CCND1 14.0 % (8) 50.0 % 25.0 %
In bold are indicated amplicons that were frequently detected (≥50 %) in tumors of each category
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MCM10 genes (upregulated) and GRP, CX3CR1, and
FAM198B (downregulated). We used the network analysis
tool of IPA software to reveal regulatory interconnections
among these genes. The network with the highest score
(26) connected 12 of the deregulated genes with 23 addi-
tional ones, showing an enrichment of the categories of
Cellular Movement, Hematological System Development
and Function, Immune Cell Trafficking (Fig. 5), in which
the S100A8 gene plays a central role.
Breast tumors with LVI exhibited 11 upregulated and 11
downregulated genes compared to negative tumors (p value
<0.05 and fold change of |2.5|). The following four upregu-
lated genes exhibited a concordant CNA pattern in tumors
with LVI: UMOD (gains) and ARSG, MYCBPAP, and MED1
(gains and high-copy gains). The 22 deregulated genes were
evaluated using the network analysis tool of IPA software. The
more relevant network (score 12) connected seven of the
differentially expressed genes with additional 28 genes, which
showed an enrichment of the categories of Cellular Develop-
ment, Cellular Growth and Proliferation, Hematological
System Development and Function. In this network, the
MED1 gene appears to play a central role (Supplementary
Figure S2).
Summary of the relevant genomic regions and selected genes
Table 5 presents a summary of the relevant genomic regions
and genes revealed in this work in association either with
histologic grade III tumors or with LVI. Data include some
of the significant recurrent CNAs, highlighting relevant gene
content, as well as three newly detected small-scale rearrange-
ments, and differentially expressed genes possibly deregulated
by copy number changes.
Discussion
Increased numbers of CNAs are expected to be associated
with tumor aggressiveness [12]; accordingly, we detected a
Fig. 3 Homozygous deletion affecting a 1.5 Mb genomic region at
12p13.3, detected in a high-risk breast tumor (histologic grade III with
lymphovascular invasion, MIC82). a Array-CGH genomic profile of the
breast carcinoma -the deletion at chromosome 12 is indicated by a red
box. b Array-CGH profile of chromosome 12, highlighting the ∼1.5 Mb
deletion at 12p13.3 (in red). c The affected genomic segment at 12p13.3
is depicted by the UCSC Genome Browser; this region encompasses five
genes, including RERGL (marked by a black box) and PIK3C2G
Tumor Biol.
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particular augmentation of the number of genomic gains in
histologic grade III breast tumors. Despite the fact that LVI is
also associated with high-risk breast cancer, no differences in
the total number of CNAs were detected in our study consid-
ering the LVI status. Taken together, our data corroborate
previous studies showing an accumulation of genomic
alterations in more aggressive breast tumors, although it also
suggests that vascular invasion is a prognostic marker not
related to increased genomic instability.
CNA pattern according to histological grade
Grade III tumors exhibited a wide range of genomic aberra-
tions previously reported for this category [11, 12]; the previ-
ously reported 19q12 amplification [17] was detected in only
one grade III tumor, although gains affecting 19q12 were
identified in additional nine grade III samples, which allowed
us to narrow the critical region to a ∼537 kb segment. It is
noteworthy that all grade III tumors carrying the 19q12 gain
were found to be negative for estrogen receptor, a finding that
corroborates the link with poor outcome [11, 28].
Some regions statistically associated with grade III tumors
in our study harbor genes either frequently amplified in
Fig. 4 Copy number changes of a panel of 36 genes in all 57 breast
tumor samples grouped according to SBR grades or lymphovascular
invasion status. The copy number status of 33 breast cancer driver
genes and 3 genes (rows) identified in the present study (ADAMTS3,
HSD17B12, and RERGL) is depicted for each tumor sample (columns) by
colored squares: gains and amplifications are shown in blue and dark
blue, respectively; losses and homozygous losses are red and dark red,
respectively. a Schematic view showing the pattern of copy number
changes of the panel of 36 genes in breast tumor samples grouped
according to histologic grade. b Schematic view showing the pattern of
copy number changes of the panel of 36 genes in breast tumors grouped
according to lymphovascular invasion status
Table 4 Top differentially expressed genes (positive fold-change values
indicating upregulation and negative fold-change values indicating
donwregulation) identified between histologic grade III breast tumors
and histologic grade I+II breast tumors (left) and between breast tumors
positive or negative for lymphovascular invasion (right)
Histologic grade IIIa Lymphovascular invasion positiveb
Gene Cytoband Fold-change p value Gene Cytoband Fold-change p value
S100A8 1q21.3 22.0278 0.001 C19orf33 19q13.2 4.4608 0.021
DEFB1 8p23.1 14.2762 0.001 LGALS7B 19q13.2 3.5713 0.007
ADM 11p15.4 7.0605 0.001 CPE 4q32.3 3.0436 0.011
MMP1 11q22.2 6.7464 0.001 AGBL2 11p11.2 2.9353 0.028
MCM10 10p13 6.4085 0.001 ARSG 17q24.2 2.7475 0.044
TMSB15A Xq22.1 6.2266 0.001 UMOD 16p12.3 2.6808 0.025
SOX11 2p25.2 5.5269 0.001 C13orf31 13q14.11 2.6631 0.026
YBX2 17p13.1 5.3408 0.001 MYCBPAP 17q21.33 2.5776 0.032
KRT81 12q13.13 5.3214 0.001 CXXC4 4q24 2.5767 0.044
E2F8 11p15.1 5.2362 0.001 MED1 17q12 2.5187 0.033
NANOS1 10q26.11 5.1092 0.001 SHISA5 3p21.31 2.5084 0.002
CDC45L 22q11.21 5.0596 0.001 GFRA1 10q25.3 −4.4772 0.021
GRP 18q21.32 −8.9074 0.001 MFI2 3q29 −4.0174 0.029
CYP4X1 1p33 −8.1935 0.001 TBX21 17q21.32 −3.8633 0.038
SUSD3 9q22.31 −8.0443 0.001 KRT15 17q21.2 −3.6634 0.016
ABAT 16p13.2 −7.3311 0.001 NFASC 1q32.1 −3.3951 0.022
EVL 14q32.2 −6.9978 0.001 FZD5 2q33.3 −3.1834 0.008
KLHDC9 1q23.3 −6.9593 0.001 TCF7L1 2p11.2 −3.0653 0.047
C6orf211 6q25.1 −6.9305 0.001 MYBPC2 19q13.33 −2.8301 0.021
NEFH 22q12.2 −6.3975 0.001 CRABP1 15q25.1 −2.7727 0.017
CX3CR1 3p22.2 −5.3859 0.001 CIB2 15q25.1 −2.5553 0.018
SMOC2 6q27 −5.3324 0.001 DUSP3 17q21.31 −2.5391 0.001
BTG2 1q32.1 −5.3206 0.001
FAM198B 4q32.1 −5.0859 0.001
CCDC74B 2q21.1 −5.0592 0.001
aHistological grade III: p value <0.001 and fold change of |5|
b Lymphovascular invasion positive: p value <0.05 and fold change of |2.5|
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aggressive breast cancer such as the oncogenes MYC (8q24)
and CCNE1 (19q12) or already reported as deleted in breast
tumors such asMTAP (9p21) [30]. The 8q22 gain is reportedly
related to poor prognosis and chemoresistance possibly due to
the activation ofMTDH [33], although the 8q22 segment here
detected did not harbor this gene and included the cancer gene
COX6C, which is involved in oxidative metabolism, upregu-
lated in prostate tumors, and fusioned to HMGIC gene in
uterine leiomyomas [34, 35]. Conversely, some of the detected
regions in the present work are not strongly related to breast
cancer; recurrent losses affecting 7p22 (segment
encompassing, among others, the PMS2 gene) and 5q11-q13
(ERCC8 and XRCC4) could suggest the involvement of DNA
repair pathways in cancer progression. The 5q loss also in-
cludes FBXL17, a gene reported to be a biomarker for breast
cancer resistance [36], and MEF2C, which was previously
identified in association with breast cancer invasion [37]. The
loss at 12p12.3 includes LMO3, a key gene implicated in the
onset and progression of several cancers [38].
Consistent with the literature [12, 18, 39], the 16p gain was
detected here preferentially in low-grade tumors (33.3 % of
grade I samples and 52.9 % of grade II samples), and all of
them were estrogen-positive samples.
CNA pattern according to LVI status
Although the LVI-positive tumors were not associated with an
increased genomic instability compared to LVI-negative tu-
mors, they showed a few genomic alterations detected at a
slightly higher frequency than the negative group, such as
gains at 5p, 17q12 and 19, and losses at 8p, 11q, 18q, and
21. The most interesting alteration was an 11q24.3 loss har-
boring ARHGAP32, a gene earlier reported to be involved in
fusion events in breast cancer cell lines and to participate in
autophagy processes [40–43]. Additionally, the 16p gain was
also preferentially associated with the absence of LVI (40% of
LVI-negative tumors), which reinforces this CNA as a marker
of good prognosis [12, 18, 39].
Fig. 5 Cellular diagram of the network created by the Ingenuity Pathway
Analysis based on interactions of the set of differentially expressed genes
detected in histologic grade III breast tumors compared to grade I and
grade II tumors. Red and green nodes represent, respectively, upregulated
or downregulated genes (the intensity of the colors indicating the degree
of deregulation) in grade III breast tumors in comparison to grade I and II
tumors (Table 4); uncolored nodes represent genes automatically includ-
ed in this network because they are biologically linked to the others based
on scientific evidence. The functional categorization of this network was
Cellular Movement, Hematological System Development and Function,
Immune Cell Trafficking, with the S100A8 gene playing a central role
Tumor Biol.
Copy number status of known driver genes and new genes
proposed for breast cancer
Known breast cancer amplicons were detected as gains either
exclusively (19q12) or predominantly in grade III tumors [15,
44]. The 20q13.2 amplicon, previously associated with poor
outcome [30, 44–47], was related in our study both to high-
grade and LVI-positive tumors. We identified three new focal
rearrangements in grade III/LVI-positive breast tumors: 4q13
and 11q11 amplifications (harboring the ADAMTS3 and the
HSD17B12 genes, respectively) and a homozygous deletion at
12p12.3 (containing, among others, the RERGL gene). These
highlighted regions because of the small size and the ampli-
tude of the copy number changes indicate potential driver
genes for breast cancer. The ADAMTS3 gene belongs to the
ADAMTS metalloproteinase family that has been implicated
in tumor progression [44–46]. Overexpression of HSD17B12
was recently associated with COX2 (1q31) overexpression in
breast carcinomas [47], and in our cohort, HSD17B12 gains
were detected in association with COX2 gains, which may
indicate a new 1q31/11p11 co-amplification pattern in ER-
negative high-grade breast tumors. However, functional stud-
ies are necessary to validate the biological relevance of the
emphasized genes.
Additionally, we assembled a panel of genes exhibiting
differences in the frequency of copy number changes between
high-grade and low-grade breast tumors groups (see Table 5),
including two of those genes here reported (RERGL and
HSD17B12). Finally, the combination of frequencies of copy
number changes of two genes was detected in LVI-positive
breast cancer group: gains of ERBB2 and losses of RERGL.
Gene expression profiling
Concerning the gene expression pattern of grade III breast
tumors, the S100A8 gene, the top upregulated gene in grade III
compared to low-grade tumors, appeared to be a central gene
in the main regulatory network. This gene can act as a potent
amplifier of inflammation in autoimmunity as well as of
cancer development and metastasis [48–50]. S100A8 overex-
pression in high-grade breast tumors in comparison to low-
grade tumors has been previously reported [51] and associated
with poor prognosis, poor tumor differentiation, LVI, and
node metastasis when co-expressed with S100A9 [52]. An-
other promising candidate gene for breast cancer aggressive-
ness is MMP1, which belongs to a matrix metalloproteinase
family associated with cell growth, metastasis, and the pro-
gression of different neoplasias, including breast cancer
[53–56]. A recent paper by our group disclosed another gene
of the same family,MMP2, as a key player in the progression
of ductal carcinomas of the breast [57].
Some of the genes with the highest differential expression
(fold change >|5| for histological grade, fold change >|3| for
LVI) exhibited direct correlations between copy number
Table 5 Summary of the relevant genomic regions and genes revealed in this work in association either with histologic grade III or with lymphovascular
invasion
Relevant gene(s) Chromosomal alteration Clinical association
MYC 8q24 gain Preferentially detected in grade III samples
MTAP 9p21 loss Preferentially detected in grade III samples
COX6C 8q22 gain Preferentially detected in grade III samples
PMS2 7p22 loss Preferentially detected in grade III samples
ERCC8, XRCC4, FBXL17, MEF2C 5q11q13 loss Preferentially detected in grade III samples
LMO3 12p12.3 loss Preferentially detected in grade III samples
CCNE1, LOC284395, VSTM2B, POP4,
PLEKHF1, C19orf12
19q12 minimum common
region of gain
Exclusively detected in grade III negative for estrogen-receptor samples
ADAMTS3 4q13.3 amplification Detected in a grade III LVI-positive sample
HSD17B12 11p11.2 amplification Detected in a grade III LVI-positive sample
RERGL, PIK3C2G 12p12.3 homozygous
deletion
Detected in a grade III LVI-positive sample
ARHGAP32 11q24.3 loss Preferentially detected in LVI-positive samples
S100A8, MCM10 – Concordant pattern of upregulated gene expression and copy number gains in
grade III samples
GRP, CX3CR1, FAM198B – Concordant pattern of downregulated gene expression and copy number losses
in grade III samples
UMOD, ARSG, MYCBPAP, MED1 – Concordant pattern of upregulated gene expression and copy number gains/
high gains in LVI-positive samples
Several 16p gain Preferentially detected in both low-grade and LVI-negative samples (exclu-
sively estrogen-receptor-positive tumors)
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changes and expression levels, such as gains affecting S100A8
and MCM10, which suggests that expression levels could be
driven by CNAs [17, 58, 59]. We also detected a downregu-
lation pattern for RERG, a gene from the family of the
abovementioned deleted RERGL gene.
Regarding the LVI tumors, the most upregulated gene in
the LVI-positive group compared to the negative group was
C19orf33 which is also known as IMUP (immortalization
upregulated protein), a gene previously shown to be
overexpressed in lung, colon, and ovarian carcinoma cell lines
[60, 61]. Another remarkable upregulated gene was
LGALS7B, a basal cell marker which enhances metastasis to
the lungs and bones in breast cancer [62]. Additionally, the
upregulated MED1 gene, earlier reported in association with
metastasis and therapy resistance in breast tumors [63], was
uncovered as a relevant gene in a network enriched for genes
in the categories of Cellular Growth and Proliferation and
Hematological System Development and Function. A concor-
dant pattern of association between CNAs and the expression
profile was detected in our study for some genes already
implicated in invasion and metastasis, such as gains and
amplifications of MYCBPAP and MED1 [63, 64]. Further-
more, downregulated genes in tumors exhibiting LVI included
MFI2, a gene associated with breast cancer metastasis when
downregulated [65].
Conclusion
Therefore, we could delineate a group of genomic alterations
and relevant genes (see Table 5) that seems to be associated
with high-grade breast cancer as well as with LVI. We recog-
nize that histologic grade and LVI are easily evaluated in
routine histological analysis, but CNA screening upon the
diagnosis of low-grade breast tumors could assist in the iden-
tification of potentially more aggressive tumors requiring
further investigation. Our study has shed some light on the
molecular players involved in two highly relevant prognostic
factors and may enable a better understanding of the mecha-
nisms of breast cancer aggressiveness.
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